Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$7.70 +1.4%	$8.02	$3.76 ▼ $46.80	$47.37M	2.77	63,817 shs	54,558 shs
IMUC EOM Pharmaceutical	$0.07 +8.2%	$0.09	$0.01 ▼ $0.21	$9.21M	-0.01	2,425 shs	7,882 shs
OSTX OS Therapies	$2.06 -4.2%	$1.79	$1.12 ▼ $7.00	$67.99M	N/A	730,258 shs	484,126 shs
TELO Telomir Pharmaceuticals	$1.49 -5.1%	$1.67	$1.12 ▼ $8.40	$44.35M	-0.67	7.84 million shs	435,724 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	0.00%	+0.13%	-14.82%	+31.85%	-37.53%
IMUC EOM Pharmaceutical	0.00%	-22.22%	-5.81%	-34.94%	-39.33%
OSTX OS Therapies	0.00%	+19.08%	+22.62%	+25.61%	-35.83%
TELO Telomir Pharmaceuticals	0.00%	-4.49%	+23.14%	-40.40%	-60.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALGS Aligos Therapeutics	4.4323 of 5 stars	3.5	4.0	0.0	4.8	2.5	1.7	0.6
IMUC EOM Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	2.2665 of 5 stars	3.7	0.0	0.0	0.0	2.3	0.8	0.6
TELO Telomir Pharmaceuticals	2.6577 of 5 stars	3.8	2.0	0.0	0.0	2.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	3.00	Buy	$70.00	809.09% Upside
IMUC EOM Pharmaceutical	0.00	N/A	N/A	N/A
OSTX OS Therapies	3.40	Buy	$18.00	773.79% Upside
TELO Telomir Pharmaceuticals	3.50	Strong Buy	$15.00	906.71% Upside

Current Analyst Ratings Breakdown

Latest IMUC, ALGS, TELO, and OSTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/14/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/30/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$3.17M	14.92	N/A	N/A	$16.56 per share	0.46
IMUC EOM Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$131.21M	-$19.79	N/A	N/A	N/A	-2,337.24%	-22.41%	-12.09%	11/5/2025 (Estimated)
IMUC EOM Pharmaceutical	-$1.89M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	-$7.79M	-$0.86	N/A	N/A	N/A	N/A	N/A	-569.57%	8/19/2025 (Confirmed)
TELO Telomir Pharmaceuticals	-$16.53M	-$0.54	N/A	N/A	N/A	N/A	-5,240.54%	-1,694.68%	N/A

Latest IMUC, ALGS, TELO, and OSTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	TELO Telomir Pharmaceuticals	-$0.08	-$0.17	-$0.09	-$0.17	N/A	N/A
8/6/2025	Q2 2025	ALGS Aligos Therapeutics	-$2.35	-$1.53	+$0.82	-$1.53	$0.43 million	$0.97 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
IMUC EOM Pharmaceutical	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	6.31	6.31
IMUC EOM Pharmaceutical	N/A	N/A	N/A
OSTX OS Therapies	N/A	0.76	0.76
TELO Telomir Pharmaceuticals	N/A	0.75	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
IMUC EOM Pharmaceutical	N/A
OSTX OS Therapies	N/A
TELO Telomir Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	4.80%
IMUC EOM Pharmaceutical	3.28%
OSTX OS Therapies	13.80%
TELO Telomir Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	90	6.15 million	5.86 million	No Data
IMUC EOM Pharmaceutical	3	126.50 million	122.35 million	Not Optionable
OSTX OS Therapies	N/A	31.62 million	N/A	N/A
TELO Telomir Pharmaceuticals	1	29.76 million	N/A	N/A

IMUC, ALGS, TELO, and OSTX Headlines

Recent News About These Companies

TELO Makes Progress Toward Human Trials

August 15 at 6:14 PM | msn.com

Telomir-1 inhibits key histone demethylase enzymes in vitro

August 12, 2025 | bioworld.comB

Telomir Pharmaceuticals (TELO) Projected to Post Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic ...

August 8, 2025 | kansascity.comK

Telomir Flat on Trial Data Release

August 7, 2025 | baystreet.ca

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction

August 7, 2025 | accessnewswire.comA

Telomir Pharmaceuticals (TELO) Expected to Announce Earnings on Tuesday

August 6, 2025 | marketbeat.com

Telomir Pharmaceuticals Announces Promising Preclinical Results

July 26, 2025 | theglobeandmail.com

Telomir Pharmaceuticals stock surges on promising Progeria treatment results

July 25, 2025 | investing.com

TELO Announces Another Important Breakthrough

July 25, 2025 | finance.yahoo.com

Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's

July 24, 2025 | accessnewswire.comA

Telomir Pharmaceuticals (NASDAQ:TELO) Trading Down 5% - Here's What Happened

July 23, 2025 | marketbeat.com

Telomir Pharmaceuticals Skyrockets 150% on Breakthrough Preclinical Cancer Results

July 18, 2025 | msn.com

Telomir Pharmaceuticals stock soars after promising cancer treatment data

July 18, 2025 | investing.com

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger Gains

July 18, 2025 | msn.com

Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin

July 18, 2025 | accessnewswire.comA

Telomir says data show Telomir-1 reversed epigenetic silencing

July 17, 2025 | msn.com

Telomir Pharmaceuticals Reveals Promising Preclinical Cancer Results

July 17, 2025 | tipranks.com

Telomir Pharmaceuticals Inc News (TELO) - Investing.com

July 1, 2025 | investing.com

Telomir Pharmaceuticals Reports Positive Preclinical Data

June 18, 2025 | tipranks.com

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging

June 18, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUC, ALGS, TELO, and OSTX Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$7.70 +0.11 (+1.45%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$7.70 +0.00 (+0.06%)

As of 08/15/2025 07:50 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

EOM Pharmaceutical OTCMKTS:IMUC

$0.07 +0.01 (+8.17%)

As of 08/15/2025 12:46 PM Eastern

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

OS Therapies NYSE:OSTX

$2.06 -0.09 (-4.19%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.08 +0.02 (+0.97%)

As of 08/15/2025 07:25 PM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Telomir Pharmaceuticals NASDAQ:TELO

$1.49 -0.08 (-5.10%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.48 -0.01 (-0.67%)

As of 08/15/2025 07:46 PM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time